%0 Journal Article
%T Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors
%A Sue Ellen Verbrugge
%A Marjon Al
%A Yehuda G Assaraf
%A Denise Niewerth
%A Johan van Meerloo
%A Jacqueline Cloos
%A Michael van der Veer
%A George L Scheffer
%A Godefridus J Peters
%A Elena T Chan
%A Janet L Anderl
%A Christopher J Kirk
%A Sonja Zweegman
%A Ben AC Dijkmans
%A Willem F Lems
%A Rik J Scheper
%A Tanja D de Gruijl
%A Gerrit Jansen
%J Experimental Hematology & Oncology
%D 2013
%I BioMed Central
%R 10.1186/2162-3619-2-2
%X Here we studied the molecular basis of acquired resistance to BTZ in JY human B lymphoblastic cells following prolonged exposure to this drug and examined possibilities to overcome resistance by next generation PIs and anti-CD20/rituximab-mediated complement-dependent cytotoxicity (CDC).Characterization of BTZ-resistant JY/BTZ cells compared to parental JY/WT cells revealed the following features: (a) 10¨C12 fold resistance to BTZ associated with the acquisition of a mutation in the PSMB5 gene (encoding the constitutive ¦Â5 proteasome subunit) introducing an amino acid substitution (Met45Ile) in the BTZ-binding pocket, (b) a significant 2¨C4 fold increase in the mRNA and protein levels of the constitutive ¦Â5 proteasome subunit along with unaltered immunoproteasome expression, (c) full sensitivity to the irreversible epoxyketone-based PIs carfilzomib and (to a lesser extent) the immunoproteasome inhibitor ONX 0914. Finally, in association with impaired ubiquitination and attenuated breakdown of CD20, JY/BTZ cells harbored a net 3-fold increase in CD20 cell surface expression, which was functionally implicated in conferring a significantly increased anti-CD20/rituximab-mediated CDC.These results demonstrate that acquired resistance to BTZ in B cells can be overcome by next generation PIs and by anti-CD20/rituximab-induced CDC, thereby paving the way for salvage therapy in BTZ-resistant disease.Since the initial approval of rituximab, a monoclonal antibody against CD20, in 1997, it has become the cornerstone in the treatment of B cell lymphoproliferative diseases [1]. Additionally, B cells play a pivotal role in the pathogenesis of inflammatory autoimmune disorders such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), for which reason over the past decade rituximab has been added as B cell depleting therapy of auto-immune diseases [2-6]. However, it is well recognized that a considerable number of patients are either primary resistant to rituximab, or
%K Proteasome inhibitors
%K Anti-CD20/rituximab therapy
%K B cells
%K Autoimmune disorders
%K Resistance
%U http://www.ehoonline.org/content/2/1/2